Reportlinker Adds Global Anti-Infectives Industry
NEW YORK, March 8 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Global Anti-Infectives Industry
http://www.reportlinker.com/p0181107/Global-Anti-Infectives-Industry.html
This report analyzes the worldwide markets for Anti-Infectives in US$ Million. The report provides separate comprehensive analytics for US, Japan, Europe, and Rest of World. Annual forecasts are provided for each region for the period 2006 through 2015. The report profiles 77 companies including many key and niche players worldwide such as Abbott Laboratories, Alcon Pharmaceuticals Ltd., Astellas Pharma, Inc., AstraZeneca PLC , Bayer HealthCare AG , Bristol-Myers Squibb Co., Boehringer Ingelheim, Cubist Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited, Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline Plc, . F. Hoffmann-La Roche, Ltd., Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer, Inc., Sanofi-Aventis SA, and Wyeth Pharmaceuticals, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
ANTI-INFECTIVES MCP-6156
A GLOBAL STRATEGIC BUSINESS REPORT
CONTENTS
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-3
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW & DYNAMICS II-1
Introduction II-1
Anti-Infective Drugs - Mechanism of Action II-1
Increasing Drug Resistance - A Major Challenge to Reckon With II-1
Antibacterial Resistance Costs High II-1
Novel Approaches to Combat Drug-Resistant Strains II-2
Combination Therapy II-2
New Approach to Directly Target Illness Rather than Infection II-2
Antivirals Directed at Human Targets II-2
Immunomodulation II-2
Antivirulence II-2
Select Companies Involved in Anti-Virulence Drug Research II-3
Pipeline Analysis of Anti-Infectives by Therapeutic Class II-3
Table 1: Anti-Infectives Pipeline by Therapeutic Class and
Development Stage:(includes corresponding Graph/Chart) II-3
Injectables Gain Traction II-4
Market Outlook II-4
Anti-Bacterials Drive Global Anti-Infectives Market II-4
Table 2: World Market for Anti-Infectives (2008): Percentage
Share Breakdown of Value Sales by Therapeutic Class -
Anti-Bacterials, Anti-Virals, Anti-Fungals, and Others
(includes corresponding Graph/Chart) II-5
Anti-Virals - A Significant Market II-5
Original Brands Leads the Supreme II-5
Table 3: Global Market for Anti-Infectives by Licensing
Status (2006-07): Percentage Share Breakdown of Value Sales
for Branded, Licensed Brands, Unbranded Drugs, and Other
Drugs (includes corresponding Graph/Chart) II-5
United States - The Largest Anti-infectives Market Globally II-6
Table 4: World Market for Anti-Infectives by Geographic
Region (2010): Percentage Share Breakdown for US, Japan,
Europe, and Rest of World (includes corresponding
Graph/Chart) II-6
Table 5: World Market for Anti-Infectives: Breakdown of
Select Geographic Regions/Country by Value Growth Potential
for the Period 2006-2015 (includes corresponding
Graph/Chart) II-6
Europe - The Second Leading Worldwide Market for Anti-Infectives II-6
Competitive Landscape II-7
Table 6: Worldwide Anti-Infectives Market by Leading Players
(2007): Percentage Share Breakdown of Value Sales for Glaxo
SmithKline, Merck, Pfizer, Novartis, Gilead Sciences, Abbott,
Wyeth, Sanofi-Aventis, Bristol-Myers Squibb, Johnson &
Johnson (includes corresponding Graph/Chart) II-7
Table 7: Leading Anti-Infective Companies Worldwide and their
Brands: Value Sales for the year 2008 (includes corresponding
Graph/Chart) II-8
GlaxoSmithKline Portfolio of Anti-Infectives - Breakdown by
Therapeutic Class II-9
2. ANTI-BACTERIALS MARKET II-10
Market Estimates and Forecasts II-10
Market Analysis by Drug Class II-10
Table 8: Worldwide Market for Anti-Bacterials by Major Drug
Class (2008): Percentage Share Breakdown for Cephalosporins,
Macrolides, Fluoroquinolones, Penicillins, and Others
(includes corresponding Graph/Chart) II-10
Market Analysis by Region II-10
Competition in Anti-Bacterials Market II-11
Table 9: World Anti-Bacterials Market (2008): Break-Up of
Value Sales (US$ Billion) for Leading Drugs (includes
corresponding Graph/Chart) II-11
Global Market Outlook II-12
Antibacterial Resistance - A Key Growth Dampener II-12
Antibiotic-Resistant Bacteria by Type II-12
Bacterial Resistance to Most Commonly Used Antibacterial Drug
Class: Incidence Level in Select Countries II-12
Generic Competition Intensifies II-13
Patent Expiries Commoditize Antibiotics II-13
Patent Expiries of Major Anti-Bacterial Drugs II-13
R&D Initiatives Imperative for Developing Novel Drugs to
Combat Drug-Resistant Strains II-14
Hospital Market for Gram-Positive Antibacterials to Witness
Encouraging Gains II-14
Anti-MRSA Antibiotics Find Their Way II-14
What are Anti-bacterials? II-15
Taxonomy of Anti-bacterials II-15
Classification of Anti-bacterials based on Mechanism of Action II-16
Antibacterial Drug Classes II-16
Penicillin II-16
Cephalosporins II-16
Side Effects II-17
Fluroquinolones II-17
Side Effects II-17
Tetracyclines II-17
Treatment II-17
Side Effects II-18
Macrolides II-18
Treatment II-18
Side Effects II-18
Others II-18
Classification based on the Process of Suppressing or Killing
Bacteria II-18
Bactericidal or Bacteria Destroying Drugs II-19
Bacteriostatic Drugs II-19
Bacterial Spectrum II-19
Use of Antibacterial Drugs: An Overview II-19
Phage Therapy, a Promising Approach for Bacterial Infections II-19
How Does Phage Therapy Works? II-20
Treatment and Application of Phase Therapy II-20
Phages for Antibiotic-Resistant Bacteria II-20
Companies Involved in Phage Therapy Research II-21
3. ANTI-VIRALS MARKET II-22
Market Estimates and Forecasts II-22
Five Major Anti-Virals Dominate the Antivirals Market II-22
Players Active in Anti-Virals Market II-22
Table 10: Major Anti-Viral Drugs of GSK and Bristol-Myers
Squibb: Annual Sales for the year 2008 (includes
corresponding Graph/Chart) II-23
Market Leaders In 2008: A Review II-23
Table 11: World Anti-Virals Market (2008): Break-Up of Value
Sales (US$ Billion) For Leading Drugs (includes
corresponding Graph/Chart) II-24
Key Trends and Issues II-24
Preventative Antivirals Gain Significance II-24
Table 12: Global Market for Anti-Virals (2007): Percentage
Share Breakdown by Category - Antiviral Therapeutics,
Vaccines, Monoclonal Antibodies, and Others (includes
corresponding Graph/Chart) II-25
R&D Initiatives Abound in Antivirals Market II-25
Companies Involved in Late-Stage Development of Anti-virals II-25
Companies Involved in Phase II Clinical Studies of Anti-virals II-26
Companies Involved in Phase I Clinical Studies of Anti-virals II-26
Select Companies in Pre-clinical Development Phase of Anti-
virals II-27
Development of Direct Targeted Antiviral Therapies II-27
New Novel Anti-Viral Peptides II-27
siRNA Shows Antiviral Potential II-27
Combination Drug Therapy Gains Popularity II-28
Microbiocides, a New Way to Fight STD and HIV Infections II-28
What are Anti-Virals? II-29
Emergence of Antivirals II-29
Types of Antivirals II-29
Entry Blockers II-29
Drugs in the Market II-30
Viral Component Replication Blockers II-30
Viral Component Assimilation Blockers II-30
Antisense Molecules II-30
Synthetic Ribozymes II-30
Protease Inhibitors II-31
Blockers for Release of Completed Viruses from the Host Cell II-31
Other Types of Antivirals II-31
Interferons II-31
Synthetic Monoclonal Antibodies II-31
Major Viral Infections & Related Drugs II-32
Human Immunodeficiency Virus (HIV) II-32
HIV Treatment - The Largest in Anti-Virals Sector II-32
Major Anti-HIV/AIDS Drugs by Category II-32
Nucleoside Reverse Transcriptase Inhibitors (NRTIs) II-33
Major Nucleoside Reverse Transcriptase Inhibitors (NRTIs): II-33
Epivir (Lamivudine) II-33
Retrovir (Zidovudine)* II-33
Combivir (Epivir+Retrovir) II-33
Videx (Didanosine) II-34
Zerit (Stavudine) II-34
Hivid (Zalcitabine) II-34
Protease Inhibitors (PIs) II-34
Major Protease Inhibitors: II-34
Norvir (Ritonavir) II-34
Kaletra (Lopinavir+Ritonavir) II-35
Invirase (Saquinavir) II-35
Fosamprenavir II-35
Integrase Inhibitors (IIs) II-35
ISENTRESS II-35
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) II-35
Entry Blockers II-35
Fusion Inhibitors II-36
Fuzeon (Enfuvirtide) II-36
Antiviral siRNAs II-36
Drugs for HIV Infected Patients in Advanced Stage II-36
Combination Therapies For HIV Infected Patients II-36
Hepatitis Infection II-36
Acute and Chronic Hepatitis Infections II-37
Treatment Regimen for Hepatitis Infection II-37
Interferons II-37
Standard Interferons II-37
Pegylated Interferons II-38
Ribavirin II-38
Types of Hepatitis Infection based on Strains II-38
Hepatitis A Virus (HAV) Infection II-38
Hepatitis B Virus (HBV) Infection II-39
Treatment for Chronic HBV Infection II-39
Vaccines Dominate the Category II-39
Antiviral Drugs for Chronic HBV Infection II-39
Major Anti-HBV Drugs: II-40
Hepatitis C Virus (HCV) Infection II-40
Treatment for Chronic Hepatitis C Infection II-40
Some Alternative Treatments II-41
Drugs in Pipeline: II-41
Hepatitis C - Drugs in Pipeline As on March 2008 II-41
Hepatitis D Virus (HDV) Infection II-41
Hepatitis E Virus (HEV) Infection II-42
Herpes Simplex Virus (HSV) Infection II-42
Treatment for HSV Infection II-42
Major HSV Drugs Worldwide and their Patent Expiries II-43
Antivirals for HSV Infection II-43
Select HSV Infection Drugs II-43
Zovirax (Aciclovir) II-43
Famvir (Famciclovir) II-43
Foscavir (Foscarnet) II-44
Valtrex (Valaciclovir) II-44
Vectavir/Denavir (Penciclovir) II-44
Abreva (Docosanol) II-44
Ophthalmic Viral Infections & Related Drugs II-44
Cytovene (Ganciclovir) II-44
Vistide (Cidofovir) II-44
Foscavir (Foscarnet) II-44
Human Papilloma Virus (HPV) II-45
Treatment for HPV Infection II-45
Respiratory Viruses Infections II-45
Influenza Virus II-45
Treatment for Influenza II-45
Major Influenza Drugs Profile II-46
Symmetrel® (Amantadine) II-46
Flumadine (Rimantadine) II-46
Tamiflu (Oseltamivir) II-46
Relenza (Zanamivir) II-46
Respiratory Syncytial Virus (RSV) Infection II-46
Treatment for RSV and other Respiratory Viral Infections II-46
Other Types of Viral Diseases II-46
Treatment for Other Viral Diseases II-47
4. ANTI-FUNGALS MARKET II-48
Anti-Fungals Market - A Quick Review II-48
Current and Future Analysis II-48
Anti-fungals: An Introduction II-48
Classification of Anti-Fungal Drugs by Class II-48
Allylamines II-49
Select Systemic and Topical Anti-Fungal Drugs Classified
under Allylamines Group II-49
Azoles II-49
Select Systemic and Topical Anti-Fungal Drugs Classified
under Azoles Group II-49
Polyene Macrolides II-50
Select Systemic and Topical Anti-Fungal Drugs Classified
under Polyene Macrolides Group II-50
Others II-50
Other Systemic and Topical Anti-Fungal Drugs II-50
Fungal Infections & Treatment II-50
Aspergillosis - Disease & Symptoms II-50
General Syndromes of Aspergillosis & Treatment Options II-51
Pulmonary Aspergillosis II-51
Aspergilloma II-51
Invasive Aspergillosis II-51
Select Drugs Used for the Treatment of Invasive Aspergillosis II-52
Blastomycosis - Disease & Symptoms II-52
Blastomycosis Treatment: Azoles the Preferred Choice II-52
Select Drugs or Medications Used For Blastomycosis Fungal
Infection Treatment II-53
Candidiasis - Disease & Symptoms II-53
General Syndromes of Candidiasis & Treatment Options II-53
Mucocutaneous Candidiasis II-53
Treatment Options II-54
Select Drugs or Medications Used for the Treatment of
Cutaneous Candidiasis II-55
Invasive Candidiasis II-55
Treatment Options II-56
Cryptococcosis & Clinical Syndromes II-56
Treatment of Cryptococcosis II-56
Select Drugs Used for the Treatment of Cryptococcosis II-57
Histoplasmosis - Disease and Symptoms II-57
Treatment Options for Histoplasmosis II-57
Select Drugs Used for the Treatment of Histoplasmosis II-58
5. AN OVERVIEW OF VACCINES MARKET II-59
Introduction II-59
Serum Institute of India Ltd. - A Major Player in Vaccines Market II-59
Other Major Players Active in Vaccines Market II-59
Table 13: Vaccines Portfolio of GlaxoSmithKline and Merck:
Breakdown of Annual Sales (in US$ Million) for the year 2008
(includes corresponding Graph/Chart) II-60
Select Infectious Diseases and Vaccines II-60
Infectious Diseases II-60
Diphtheria II-60
Tetanus (Lockjaw) II-61
Pertussis (Whooping Cough) II-61
Vaccines for Diphtheria, Tetanus and Pertussis II-61
Select Diphtheria Vaccines by Company II-61
DTaP - A Combination Vaccine for Diphtheria, Tetanus and
Pertussis II-62
DT - A Combination Vaccine for Diphtheria and Tetanus II-62
Td - The Tetanus and Diphtheria Vaccine II-62
Tdap - A Vaccine for Tetanus, Diphtheria and Pertussis II-62
Measles II-62
Live, Attenuated (Freeze-Dried) Measles Vaccine II-63
Mumps II-63
MMR - A Combination Vaccine for Measles, Mumps and Rubella II-63
Side Effects of MMR Vaccine II-63
Polio & Vaccines II-64
Influenza Vaccines II-64
Hepatitis B Vaccine II-64
HPV Infection Vaccines II-65
HIV Vaccines - Research Clipped by Lack of Funds II-65
6. RESEARCH & DEVELOPMENT II-66
Emergent Begins Phase I/II Clinical Studies of AIG for Anthrax
Treatment II-66
Novartis Initiates Phase IIb Clinical Trials of Albuferon® II-66
Schering-Plough Concludes Phase III Trials for INTRON A® Plus
REBETOL™ Combination Therapy II-66
Progenics Advances Research on New Antibody Therapy for HIV II-67
Forest Labs Announces Encouraging Phase III Results of
Ceftaroline II-67
Pharmasset Completes Phase 1a Trial of PSI-7851, Initiates
Phase1b Study II-68
Roche Announces Positive Results of PEGASYS/ COPEGUS
Combination Therapy II-68
Novartis Announces Phase III Results of Menveo® Vaccine II-68
Discovery Laboratories Announces Pre-Clinical Results of
SURFAXIN® II-69
Emergent Commences Phase II Clinical Study of Typhoid Vaccine II-69
Enanta Begins Phase I Trial of EDP-322, the First MRSA-Active
Bicyclolide II-69
Roche, Pharmasset, InterMune Being Oral Anti-Virals Dual-
Combination Study II-70
ANRS, Pharmasset, Gilead Initiate Clevudine + Viread® Clinical
Trials II-70
7. PRODUCT LAUNCHES II-72
Rx Africa (Ethiopia) to Introduce Generic Pharmaceuticals II-72
Destiny Pharma Develops New Metallo-Porphyrin Anti-Bacterial Drug II-72
Galderma Laboratories Launches EpiduoTM Gel II-72
Ranbaxy Rolls Out Generic Valtrex II-72
Glenmark Introduces Onabet Topical Antifungal Cream II-73
MIT Scientists Develop a New Antibiotic, Rhodostreptomycin II-73
Watson Pharma Introduces Biaxin XL's Generic Version II-73
Taisho Toyama Pharmaceutical Rolls Out Zosyn® II-73
GSK Launches ALTARGO® in the UK II-74
Toyama Launches New Garenoxacin Quinolone Antibiotic II-74
Wockhardt to Introduce Cefprozil in the US II-74
MSD India Launches Invanza in India II-75
Macrolide Antibiotic Developed in the US II-75
University of Michigan Devises NMR Spectroscopy for Antibiotics II-75
Glycopeptide-Cephalosporin Antibiotics Developed in the US II-75
8. RECENT INDUSTRY ACTIVITY II-76
Merck Merges with Schering-Plough II-76
Beactica and Cubist Sign Agreement II-76
Akela Pharma Acquires Nventa Biopharmaceuticals II-76
GSK and Pfizer Establish New JV for Developing Anti-HIV Drugs II-76
Evotec and Cubist Ink Research Pact for Fragment-Based Drug
Discovery II-77
Grindeks Commences Production of Anti-flu Drug, Rimantadine-
Grindeks II-77
Galapagos Expands Partnership with GSK II-77
GSK Acquires Stiefel II-78
The Medicines Company Acquires Targanta II-78
Tibotec Signs Licensing and Partnership Deal with Gilead II-78
Abbott Buys Ibis Biosciences II-79
Elder and Strides on Expansion Mode II-79
Kemin Industries Acquires Amalyte Pharmaceuticals II-79
Valeant Pharmaceuticals International Acquires EMO-FARM II-79
Pfizer Inks Agreements with Claris Lifesciences and Aurobindo
Pharma II-80
moksha8 Extends Partnership with Roche II-80
Akorn Signs Agreement with Eli Lilly and Company II-80
Access Pharmaceuticals Acquires MacroChem II-80
Vertex Pharmaceuticals Acquires ViroChem Pharma II-81
sanofi-aventis Acquires Laboratorios Kendrick II-81
DSM Enters into Joint Venture with North China Pharmaceutical
Group II-81
NovaBay Inks Agreement with Medical University of Innsbruck II-82
Tibotec Collaborates with Global Alliance for TB Drug Development II-82
DSM Aired Plans to Divest DSM Deretil II-82
3i to Buy Alpharma Unit II-83
Three Rivers Acquires Infergen® HCV Drug From Valeant II-83
ULL Establishes New Antibiotics Unit in Himachal Pradesh II-83
Biocat to Expand Presence in the Indian Market II-83
Ranbaxy Signs Agreement with Merck II-84
Zydus Acquires Controlling Interest in Simayla Pharmaceuticals II-84
Novartis to Acquire Protez II-84
Marksans Acquires Relonchem II-85
Orchid Signs Licensing Agreement with Merck II-85
Forest and Novexel Sign Licensing Agreement II-85
Sanofi-aventis Collaborates with Novozymes II-85
Janssen-Cilag International Obtains Marketing Authorization
for INTELENCETM II-86
Nastech Pharmaceutical Company Changes Name to MDRNA II-86
Galderma Laboratories Acquires CollaGenex Pharmaceuticals II-86
Emergent BioSolutions Forges Joint Venture with the University
of Oxford II-87
Emergent BioSolutions to Acquire Recombinant Flu Vaccine,
FluBlok® II-87
AstraZeneca Acquires Arrow Therapeutics II-88
Cubist Submits INDs for CB-182,804 and CB-183,315 II-88
SRI International Partners with Blanca Pharmaceuticals to
Develop Antibiotics II-89
Allergan Acquires Esprit Pharma II-89
GSK And Anacor Team Up for Boron Chemistry-Based Antibiotics
and Antivirals II-89
J&J PRD Seeks FDA Approval for Doripenem Antibiotic II-90
J&JPRD Seeks FDA Approval for Ceftobiprole II-90
GSK to Cease Sale of Amprenavir Protease Inhibitor II-90
Iroko Bags Canadian Rights to Vancocin® II-91
AstraZeneca Purchases Biologics Production Facility from DSM
Biologics II-91
Depomed Expands Agreement with Watson Pharmaceuticals II-91
Depomed Terminates Agreement with Esprit Pharma II-91
Phylogica and Dynamic Microbials Inks Agreement II-91
Pharmasset Collaborates with University of Cincinnati II-92
Homeland Safety International Acquires Majority Stake in PLC
Marketing II-92
Ecopia and Caprion Merge to Form Thallion Pharmaceuticals II-92
9. DRUG APPROVALS II-93
FDA Clears Extended Therapy with INTRON A in Chronic HCV Patients II-93
Abbott Obtains EC Approval for Kaletra® in Treating HIV Patients II-93
Tibotec Gets EC Clearance for PREZISTA® in Treating HIV Patients II-93
Health Canada Approves Anti-HIV-1 Drug, ISENTRESS® II-93
Mylan Receives FDA Approval for Linezolid 600 mg Tablets II-94
Rottapharm/Madaus Obtains Clearance to Market ProQuin XR in
Sweden II-94
MiddleBrook Obtains NDA Approval for MOXATAG™ II-94
Tibotec Pharmaceuticals Obtains US FDA Approval for PREZISTA® II-94
Wyeth Receives an Approvable Letter from US FDA for TYGACIL® II-94
Astellas Pharma Receives Approval from US FDA for MYCAMINE® II-95
Cubist Pharmaceuticals Receives Health Canada Approval for
CUBICIN® II-95
Cubist Receives EC Approval for Extended Use of Cubicin® II-95
GSK Receives Approval for ALTARGO® in Europe II-96
Cubist Gains Approval for CUBICIN in Taiwan and South Korea II-96
10. FOCUS ON SELECT GLOBAL PLAYERS II-97
Abbott Laboratories (USA) II-97
Alcon Pharmaceuticals Ltd. (Switzerland) II-97
Astellas Pharma, Inc. (Japan) II-98
AstraZeneca PLC (UK) II-98
Bayer HealthCare AG (Germany) II-99
Bristol-Myers Squibb Co. (USA) II-99
Boehringer Ingelheim (Germany) II-100
Cubist Pharmaceuticals, Inc. (USA) II-100
Daiichi Sankyo Company, Limited (Japan) II-101
Eli Lilly and Company (USA) II-102
Gilead Sciences, Inc. (USA) II-102
GlaxoSmithKline Plc (UK) II-103
F. Hoffmann-La Roche, Ltd. (Switzerland) II-103
Johnson & Johnson (USA) II-104
Merck & Co., Inc (USA) II-104
Novartis AG (Switzerland) II-105
Pfizer, Inc. (USA) II-106
Sanofi-Aventis SA (France) II-106
Table 14: The below table exhibits worldwide vaccines sales
of the company for the year 2008: (includes corresponding
Graph/Chart) II-107
Wyeth Pharmaceuticals, Inc. (USA) II-108
11. GLOBAL MARKET PERSPECTIVE II-109
Anti-infectives by Region: II-109
Table 15: World Recent Past, Current & Future Analysis for
Anti-Infectives by Geographic Region - US, Japan, Europe, and
Rest of World Markets Independently Analyzed by Annual
Revenues in US$ Million for the Years 2006 through 2015
(includes corresponding Graph/Chart) II-109
Table 16: World 10-Year Perspective for Anti-Infectives by
Geographic Region - Percentage Breakdown of Dollar Revenues
for the US, Japan, Europe, and Rest of World Markets for 2006,
2009 & 2015 (includes corresponding Graph/Chart) II-110
Anti-Infectives by Therapeutic Class: II-111
Table 17: World Recent Past, Current & Future Analysis for
Anti-Infectives by Therapeutic Class - Antibacterials,
Antivirals, Antifungals, and Others* Markets Independently
Analyzed by Annual Revenues in US$ Million for the Years 2006
through 2015 (includes corresponding Graph/Chart) II-111
Table 18: World 10-Year Perspective for Anti-Infectives by
Therapeutic Class - Percentage Breakdown of Dollar Revenues
for Antibacterials, Antivirals, Antifungals, and Others*
Markets for 2006, 2009 & 2015 (includes corresponding
Graph/Chart) II-112
Anti-bacterials by Region: II-113
Table 19: World Recent Past, Current & Future Analysis for
Anti-Bacterials by Geographic Region - US, and Rest of World
Markets Independently Analyzed by Annual Sales Revenues in US$
Million for the Years 2006 through 2015 (includes
corresponding Graph/Chart) II-113
Table 20: World 10-Year Perspective for Anti-Bacterials by
Geographic Region - Percentage Breakdown of Annual Sales
Revenues for the US and Rest of World Markets for 2006, 2009 &
2015 II-113
Anti-bacterials By Drug-Class: II-114
Table 21: World Recent Past, Current & Future Analysis for
Anti-Bacterials by Drug Class - Cephalosporins, Penicillins,
Fluoroquinolones, Macrolides, and Others Markets Independently
Analyzed by Annual Sales Revenues in US$ Million for the Years
2006 through 2015 (includes corresponding Graph/Chart) II-114
Table 22: World 10-Year Perspective for Anti-Bacterials by
Drug Class - Percentage Breakdown of Annual Sales Revenues for
Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, and
Others Markets for 2006, 2009 & 2015 (includes corresponding
Graph/Chart) II-115
Table 23: World Recent Past, Current & Future Analysis for
Cephalosporins by Geographic Region - US and Rest of World
Markets Independently Analyzed by Annual Sales Revenues in US$
Million for the Years 2006 through 2015 (includes
corresponding Graph/Chart) II-116
Table 24: World 10-Year Perspective for Cephalosporins by
Geographic Region - Percentage Breakdown of Annual Sales
Revenues for the US and Rest of World Markets for 2006, 2009 &
2015 II-116
Table 25: World Recent Past, Current & Future Analysis for
Penicillins by Geographic Region - US and Rest of World
Markets Independently Analyzed by Annual Sales Revenues in US$
Million for the Years 2006 through 2015 (includes
corresponding Graph/Chart) II-117
Table 26: World 10-Year Perspective for Penicillins by
Geographic Region - Percentage Breakdown of Annual Sales
Revenues for the US and Rest of World Markets for 2006, 2009 &
2015 II-117
Table 27: World Recent Past, Current & Future Analysis for
Fluoroquinolones by Geographic Region - US and Rest of World
Markets Independently Analyzed by Annual Sales Revenues in US$
Million for the Years 2006 through 2015 (includes
corresponding Graph/Chart) II-118
Table 28: World 10-Year Perspective for Fluoroquinolones by
Geographic Region - Percentage Breakdown of Annual Sales
Revenues for the US and Rest of World Markets for 2006, 2009 &
2015 II-118
Table 29: World Recent Past, Current & Future Analysis for
Macrolides by Geographic Region - US and Rest of World Markets
Independently Analyzed by Annual Sales Revenues in US$ Million
for the Years 2006 through 2015 (includes corresponding
Graph/Chart) II-119
Table 30: World 10-Year Perspective for Macrolides by
Geographic Region- Percentage Breakdown of Annual Sales
Revenues for the US and Rest of World Markets for 2006, 2009 &
2015 II-119
Table 31: World Recent Past, Current & Future Analysis for
Other Anti-bacterials by Geographic Region - US and Rest of
World Markets Independently Analyzed by Annual Sales Revenues
in US$ Million for the Years 2006 through 2015 (includes
corresponding Graph/Chart) II-120
Table 32: World 10-Year Perspective for Other Anti-bacterials
by Geographic Region - Percentage Breakdown of Dollar
Revenues for the US and Rest of World Markets for 2006, 2009
& 2015 II-120
III. MARKET
1. THE UNITED STATES III-1
A.Market Analysis III-1
HIV Market Perspective in the US III-1
HIV/AIDS - Prevalence III-1
Homosexual Males - A Significant Risk Group for HIV Infections III-2
Women - A High Risk Group for HIV/AIDS III-2
African-Americans - The Leading High Risk Ethnic Group for
HIV Infection III-2
Latinos - The Second Major Ethnic Risk Group for HIV Infection III-2
An Overview of Sexually Transmitted Diseases (STDs) III-3
Regulatory Environment III-3
Product Innovations/Introductions III-3
Strategic Corporate Developments III-5
FDA Regulations And Approvals III-11
Focus on Select Players III-13
B.Market Analytics III-21
Table 33: US Recent Past, Current & Future Analysis for
Anti-Infectives Market Analyzed with Annual Sales Revenues
in US$ Million for Years 2006 through 2015 (includes
corresponding Graph/Chart) III-21
Table 34: US Recent Past, Current & Future Analysis for
Anti-Bacterials Market by Drug Class - Cephalosporins,
Penicillins, Fluoroquinolones, Macrolides, and Others
Markets Analyzed by Annual Sales Revenues in US$ Million for
Years 2006 through 2015 (includes corresponding Graph/Chart) III-22
Table 35: US 10-year Perspective for Anti-Bacterials Market
by Drug Class - Percentage Breakdown of Dollars Sales
Revenues for Cephalosporins, Penicillins, Fluoroquinolones,
Macrolides, and Others Markets for Years 2006, 2009 & 2015
(includes corresponding Graph/Chart) III-23
2. JAPAN III-24
A.Market Analysis III-24
Infectious Disease Market Witnessing Mixed Fortunes in Japan III-24
HIV Infection Prevalence - One of the Lowest Worldwide III-24
Hepatitis C Prevalence - Widespread and Driving the
Hepatitis C Drugs Market III-25
Table 36: Leading Hepatitis C Anti-viral Products in Japan
(2008(E)): Percentage Share Breakdown for PEG-Intron,
Pegasys, Intron A, Advaferon, Sumiferon, Feron, and Others
(includes corresponding Graph/Chart) III-25
Product Innovations/Introductions III-26
Focus on Select Players III-26
B.Market Analytics III-29
Table 37: Japanese Recent Past, Current & Future Analysis
for Anti-Infectives Market - Annual Revenues in US$ Million
for Years 2006 through 2015 (includes corresponding
Graph/Chart) III-29
3. EUROPE III-30
A.Market Analysis III-30
Strategic Corporate Developments III-30
B.Market Analytics III-33
Table 38: European Recent Past, Current & Future Analysis
for Anti-Infectives Market by Geographic Region - France,
Germany, Italy, UK, Spain, and Rest of Europe Markets
Analyzed by Annual Sales Revenues in US$ Million for Years
2006 through 2015 (includes corresponding Graph/Chart) III-33
Table 39: European 10-year Perspective for Anti-Infectives
Market by Geographic Region - Percentage Breakdown of
Dollars Sales for France, Germany, Italy, UK, Spain, and
Rest of Europe Markets for Years 2006, 2009 & 2015 (includes
corresponding Graph/Chart) III-34
3a. FRANCE III-35
A.Market Analysis III-35
France - The Largest Market for Anti-Infectives in Europe III-35
Antibiotics Use Takes A Dip, As Regulatory Authorities'
Efforts Pays Off III-35
Strategic Corporate Development III-35
Focus on Select Players III-36
Sanofi-Aventis SA III-36
Table 40: The below table exhibits worldwide vaccines
sales of the company for the year 2008: (includes
corresponding Graph/Chart) III-37
B.Market Analytics III-37
Table 41: French Recent Past, Current & Future Analysis for
Anti-Infectives Market Analyzed with Annual Sales Revenues
in US$ Million for Years 2006 through 2015 (includes
corresponding Graph/Chart) III-37
3b. GERMANY III-38
A.Market Analysis III-38
Strategic Corporate Development III-38
Focus on Select Players III-38
B.Market Analytics III-40
Table 42: German Recent Past, Current & Future Analysis for
Anti-Infectives Market Analyzed with Annual Sales Revenues
in US$ Million for Years 2006 through 2015 (includes
corresponding Graph/Chart) III-40
3c. ITALY III-41
Market Analysis III-41
Table 43: Italian Recent Past, Current & Future Analysis for
Anti-Infectives Market Analyzed with Annual Sales Revenues
in US$ Million for Years 2006 through 2015 (includes
corresponding Graph/Chart) III-41
3d. THE UNITED KINGDOM III-42
A.Market Analysis III-42
Infectious Diseases - A Quick Primer III-42
Table 44: Number of new Cases, and Deaths due to Infectious
Disorders in England (2006): Breakdown by Infection Type
(includes corresponding Graph/Chart) III-42
Research and Development of New Anti-Infectives III-43
Table 45: Number of New Anti-Infectives Approved in UK
(2003-2007): Breakdown by Therapeutic Class - Anti-Virals
and Anti-Bacterials III-43
Impediments to the Development of New Anti-infectives III-43
Scientific Barriers III-43
Economic Barriers III-44
Regulatory Barriers III-44
HIV/AIDS Prevalence - On the Rise III-44
Drug Resistant HIV Strains - Incidence Rising III-45
STD - Rising Incidence Poses Health Risks III-45
Product Innovations/Introductions III-45
Strategic Corporate Developments III-46
Focus on Select Players III-48
B.Market Analytics III-50
Table 46: UK Recent Past, Current & Future Analysis for
Anti-Infectives Market Analyzed with Annual Sales Revenues
in US$ Million for Years 2006 through 2015 (includes
corresponding Graph/Chart) III-50
3e. SPAIN III-51
Market Analysis III-51
Table 47: Spanish Recent Past, Current & Future Analysis for
Anti-Infectives Market Analyzed with Annual Sales Revenues
in US$ Million for Years 2006 through 2015 (includes
corresponding Graph/Chart) III-51
3f. REST OF EUROPE III-52
A.Market Analysis III-52
Focus on Select Market III-52
Russia - Leading the Prevalence of HIV/AIDS III-52
Acute Drug Supply Shortages Risk Lives HIV Victims III-52
Strategic Corporate Developments III-52
Focus on Select Players III-54
B.Market Analytics III-56
Table 48: Rest of Europe Recent Past, Current & Future
Analysis for Anti-Infectives Market Analyzed with Annual
Sales Revenues in US$ Million for Years 2006 through 2015
(includes corresponding Graph/Chart) III-56
4. REST OF WORLD III-57
A.Market Analysis III-57
Focus on Select Markets III-57
Canada III-57
HIV/AIDS Prevalence III-57
Asia-Pacific III-57
HIV/AIDS Prevalence III-57
HIV Infection Rising Among Male III-58
Australia III-58
HIV/AIDS Prevalence III-58
Chronic Hepatitis C Prevalence III-59
Bangladesh III-59
HIV/AIDS Prevalence III-59
Cambodia III-59
HIV/AIDS Prevalence III-59
China III-59
HIV/AIDS Prevalence III-59
Antibiotics Market III-60
Antibiotics Manufacturing III-60
Carbapenem Antibiotics Hold Great Potential III-60
China Represents a Major Market for Hepatitis B Therapies III-61
India III-61
HIV/AIDS Prevalence III-61
Not-for-Profit Organizations Active in HIV/AIDS Control
and Prevention III-61
AIDS Control Programs for Rural Youths in India III-62
Anti-Infectives Market Experiencing Double- Digit Growth III-62
Table 49: Pharmaceutical Market in India (2007):
Percentage Market Share Breakdown by Therapeutic Class
(includes corresponding Graph/Chart) III-63
Competition III-63
Top 5 Drug Producers in India, and their Major Products III-63
Injectable Antibiotics Demonstrate Robust Growth III-63
New Initiative to Develop Novel Antibiotic Molecules III-64
Major Players - Hepatitis B Vaccines III-64
Product Innovations/Introductions III-64
Strategic Corporate Developments III-65
Focus on Select Players III-69
B.Market Analytics III-70
Table 50: Rest of World Recent Past, Current & Future
Analysis for Anti-Infectives Market Analyzed with Annual
Sales Revenues in US$ Million for Years 2006 through 2015
(includes corresponding Graph/Chart) III-70
Table 51: Rest of World Recent Past, Current & Future
Analysis for Anti-Bacterials Market by Drug Class -
Cephalosporins, Penicillins, Fluoroquinolones, Macrolides,
and Others Markets Analyzed by Annual Sales Revenues in US$
Million for Years 2006 through 2015 (includes corresponding
Graph/Chart) III-71
Table 52: Rest of World 10-year Perspective for
Anti-Bacterials Market by Drug Class - Percentage Breakdown
of Dollars Sales Revenues for Cephalosporins, Penicillins,
Fluoroquinolones, Macrolides, and Others Markets for Years
2006, 2009 & 2015 (includes corresponding Graph/Chart) III-72
IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 77 (including Divisions/Subsidiaries - 85)
------------------------------------------
Region/Country Players
------------------------------------------
The United States 54
Canada 1
Japan 3
Europe 16
France 2
Germany 3
The United Kingdom 3
Italy 1
Rest of Europe 7
Asia-Pacific (Excluding Japan) 10
Middle-East 1
------------------------------------------
To order this report:
Pharmaceutical Industry: Global Anti-Infectives Industry
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg |
|
Reportlinker |
|
Email: [email protected] |
|
US: (805)-652-2626 |
|
Intl: +1 805-652-2626 |
|
SOURCE Reportlinker
Share this article